Kodiak Sciences Statistics
Total Valuation
Kodiak Sciences has a market cap or net worth of $2.40 billion. The enterprise value is $2.33 billion.
| Market Cap | 2.40B |
| Enterprise Value | 2.33B |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kodiak Sciences has 62.72 million shares outstanding. The number of shares has increased by 9.97% in one year.
| Current Share Class | 62.72M |
| Shares Outstanding | 62.72M |
| Shares Change (YoY) | +9.97% |
| Shares Change (QoQ) | +1.24% |
| Owned by Insiders (%) | 5.06% |
| Owned by Institutions (%) | 70.64% |
| Float | 39.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 39.34 |
| P/TBV Ratio | 39.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.86.
| Current Ratio | 2.49 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -368.37% and return on invested capital (ROIC) is -124.49%.
| Return on Equity (ROE) | -368.37% |
| Return on Assets (ROA) | -60.45% |
| Return on Invested Capital (ROIC) | -124.49% |
| Return on Capital Employed (ROCE) | -121.71% |
| Weighted Average Cost of Capital (WACC) | 16.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +303.47% in the last 52 weeks. The beta is 2.20, so Kodiak Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | +303.47% |
| 50-Day Moving Average | 39.77 |
| 200-Day Moving Average | 32.19 |
| Relative Strength Index (RSI) | 41.55 |
| Average Volume (20 Days) | 579,898 |
Short Selling Information
The latest short interest is 10.23 million, so 16.31% of the outstanding shares have been sold short.
| Short Interest | 10.23M |
| Short Previous Month | 10.42M |
| Short % of Shares Out | 16.31% |
| Short % of Float | 25.86% |
| Short Ratio (days to cover) | 15.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -248.33M |
| Pretax Income | -241.99M |
| Net Income | -241.99M |
| EBITDA | -230.98M |
| EBIT | -248.33M |
| Earnings Per Share (EPS) | -$4.18 |
Balance Sheet
The company has $125.90 million in cash and $52.76 million in debt, with a net cash position of $73.15 million or $1.17 per share.
| Cash & Cash Equivalents | 125.90M |
| Total Debt | 52.76M |
| Net Cash | 73.15M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 61.10M |
| Book Value Per Share | 0.97 |
| Working Capital | 78.59M |
Cash Flow
In the last 12 months, operating cash flow was -$158.51 million and capital expenditures -$1.40 million, giving a free cash flow of -$159.90 million.
| Operating Cash Flow | -158.51M |
| Capital Expenditures | -1.40M |
| Depreciation & Amortization | 17.35M |
| Net Borrowing | n/a |
| Free Cash Flow | -159.90M |
| FCF Per Share | -$2.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kodiak Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.97% |
| Shareholder Yield | -9.97% |
| Earnings Yield | -10.07% |
| FCF Yield | -6.65% |
Analyst Forecast
The average price target for Kodiak Sciences is $69.00, which is 80.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $69.00 |
| Price Target Difference | 80.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |